EVALUATION OF HUMAN IMMUNOGLOBULIN EFFECTIVENESS IN PATIENTS WITH SENSORYMOTOR POLYNEUROPATHY ASSOCIATED WITH MONOCLONAL GAMMAPATHY OF UNDETERMINED SIGNIFICANCE

Introduction . A number of paraproteinemic polyneuropathy is directly linked to the monoclonal gammapathy of undetermined significance (MGUS). One of the first manifestations of MGUS in addition to the secretion of monoclonal immunoglobulin, and long before the manifestation of malignancy is polyneu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Arkhivʺ vnutrenneĭ medit͡s︡iny 2018-08, Vol.8 (4), p.278-284
Hauptverfasser: Yakovlev, A. A., Gapeshin, R. A., Smochilin, A. G., Yakovleva, M. V.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction . A number of paraproteinemic polyneuropathy is directly linked to the monoclonal gammapathy of undetermined significance (MGUS). One of the first manifestations of MGUS in addition to the secretion of monoclonal immunoglobulin, and long before the manifestation of malignancy is polyneuropathy. Materials and Methods . Were examined in 16 patients with polyneuropathy associated with MGUS in age from 53 to 78 years. Patients underwent a course of infusion therapy with human immunoglobulin in the dose of 0.4 g/kg for 5 days. Results . After treatment revealed a reduction of the manifestations of the sensory component of the neuropathy, neuropathic pain and sensitive ataxia that was confirmed by electromyographic data of stabilography, and a rating on a scale Lovett, the scale of neuropathy disability score, the questionnaire «Pain detect». The motor component of polyneuropathy had more persistent symptoms. Conclusion . Treatment with human immunoglobulin is effective in reduction of neuropathic pain and sensory ataxia and in increase of superficial and deep sensation, while the motor component of polyneuropathy had more persistent symptoms. 
ISSN:2226-6704
2411-6564
DOI:10.20514/2226-6704-2018-8-4-278-284